US 12,331,032 B2
Quinone reductase 2 inhibitor compounds and uses thereof
Christopher D. Lascola, Durham, NC (US); and Daniel T. Laskowitz, Chapel Hill, NC (US)
Assigned to DUKE UNIVERSITY, Durham, NC (US)
Appl. No. 17/285,622
Filed by DUKE UNIVERSITY, Durham, NC (US)
PCT Filed Oct. 16, 2019, PCT No. PCT/US2019/056534
§ 371(c)(1), (2) Date Apr. 15, 2021,
PCT Pub. No. WO2020/081680, PCT Pub. Date Apr. 23, 2020.
Claims priority of provisional application 62/746,870, filed on Oct. 17, 2018.
Prior Publication US 2021/0395220 A1, Dec. 23, 2021
Int. Cl. C07D 401/12 (2006.01); A61K 31/4709 (2006.01); C07D 215/02 (2006.01)
CPC C07D 401/12 (2013.01) [C07D 215/02 (2013.01); A61K 31/4709 (2013.01)] 24 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
wherein R1 is:

OG Complex Work Unit Chemistry
wherein D1, D2, D3, and D4 are each independently selected from the group consisting of hydrogen, halo, alkyl, acyl, alkoxy, aryl, heteroaryl, amino, amide, nitro, hydroxyl, thiol, sulfone, sulfoxide, nitrile, nitro, and haloalkyl, or
D1 and D2, D2 and D3, or D3 and D4 together form a fused ring that is optionally substituted,
wherein said compound is optionally substituted one, two or three times with fluoromethyl, difluoromethyl or trifluoromethyl,
or a pharmaceutically acceptable salt or prodrug thereof.